Find and Pitch Jounalists, Get Your Story Covered

Tags: biotechnology CRISPR drug development FDA Pharmaceuticals

	Profile	Recent Articles on Subject
1	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	Biotechs emerging from stealth take aim at pharma’s prime targets - about 1 month ago Pharma’s forecast for 2025: Sowing seeds of a rebound - 3 months ago 4 companies to watch in the accelerating gene editing race - 4 months ago 2024 PharmaVoice 100s: Trailblazers - 6 months ago 2024 PharmaVoice 100s: Standout Leaders - 6 months ago California is a life sciences leader. Joe Panetta has been one of its most vocal advocates. - 7 months ago Who’s winning in biotech’s tight market? - 7 months ago What pharma has learned from AI - 9 months ago Amylyx’s CEOs on their ALS setback and quest to revamp the pipeline - 9 months ago Pharma’s R&D gamble: picking pipeline winners in a risky field - 11 months ago Astellas’ science chief on the leap into new technologies - about 1 year ago ‘1 plus 1 equals 3’ — the co-CEO model in pharma - about 1 year ago The biggest questions hanging over pharma in 2024 - about 1 year ago Five years after closing the Shire deal, Takeda is ready to harvest from its latest reinvention - over 1 year ago Pharma execs sound off on trends and policies they’re tracking in 2024 - over 1 year ago A former CDC head on key R&D areas, public trust and if we learned anything from COVID-19 - over 1 year ago Does BioMarin’s CEO shuffle signal bigger changes ahead? - over 1 year ago The 2023 Red Jacket honorees - over 1 year ago Red Jacket: Helen Sabzevari, an immunotherapy pioneer - over 1 year ago PharmaVoice 100s: Clinical trial gurus - over 1 year ago The PharmaVoice 100: Standout execs - over 1 year ago
2	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	The biotech news stories you need to read today - 2 months ago Biopharma leaders lay out vision for the future of blood cancer treatment - 5 months ago STAT+: More tumult at BIO amid the company’s fourth CEO in four years - 11 months ago Lawmakers want to add more Chinese biotechs to defense list - about 1 year ago What do CEOs owe the world? - about 1 year ago The legal pathway for experimental, ultra-rare disease treatments is rocky and expensive - over 1 year ago Novartis is building a new radioligand plant in China - over 1 year ago Johnson & Johnson bets heavy on AI-driven drug discovery - over 1 year ago Why Biogen is purposefully becoming more risk averse, according to Biogen’s CEO - over 1 year ago
3	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	STAT+: Is Trump’s new order a reprieve for biotech? - 2 months ago East Asians under-represented in biopharma leadership - 4 months ago A key decision on compounding is expected this week - 4 months ago
4	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	In the crowded cardio space, it’s David vs. Goliath for small biotechs - 2 months ago Milk-based therapies could be coming. This biotech CEO is aiming to lead the way. - 5 months ago Read to lead: 6 books pharma execs swear by - 9 months ago Execs from Bayer, Kite and Orca sound off on their launch strategies for cell and gene therapies - 11 months ago 4 offbeat biotechs making a splash in the life sciences - 12 months ago How a biotech exec is leveraging Big Pharma lessons to advance tRNA - 12 months ago
5	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	Biopharma leaders lay out vision for the future of blood cancer treatment - 5 months ago
6	Angus Chen STAT News Undignified, unfunny journalist. Health, cancer coverage at STAT News. journalismhealthcancer researchSTAT News	Biopharma leaders lay out vision for the future of blood cancer treatment - 5 months ago
7	Jonathan Wosen STAT News West Coast Biotech Reporter. Formerly @sdut. Stanford PhD. UCSC alum. San Diego, California BiotechLife SciencesImmunology	Biopharma leaders lay out vision for the future of blood cancer treatment - 5 months ago STAT+: Biotech power broker John Maraganore offers advice to the next crop of entrepreneurs - over 1 year ago STAT+: Cell and gene therapy CEOs share survival strategies amid biotech slump - over 1 year ago STAT+: Failed biotech gives a rare peek inside the tough breaks — and tough choices — that led to its demise - over 1 year ago
8	John Wilkerson STAT News STAT Washington correspondent. Healthcare Journalism	STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group - 6 months ago
9	Lizzy Lawrence STAT News Medical devices reporter at STATnews. Loves news tips. medical reportingnews	STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group - 6 months ago
10	Sarah Owermohle STAT News Health reporter @STATNews. Covers Biden's agenda. Washington, District of Columbia health policyjournalism	STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group - 6 months ago

Journalists covering biotech leadership